Verona Pharma PLC Stock Research

Market Summary

USD21.46-0.42

Delayed

-1.92%

VRNA Alerts

6 major insider sales recently.

VRNA Stock Price

VRNA RSI Chart

VRNA Valuation

Market Cap

13.6B

Price/Earnings (Trailing)

-223.78

Price/Sales (Trailing)

29.6K

EV/EBITDA

-225.3

Price/Free Cashflow

-265.09

VRNA Price/Sales (Trailing)

VRNA Profitability

EBT Margin

-14944.98%

Return on Equity

-29.81%

Return on Assets

-26.48%

Free Cashflow Yield

-0.38%

VRNA Fundamentals

VRNA Revenue

Revenue (TTM)

458.0K

Revenue Q/Q

-30.61%

VRNA Earnings

Earnings (TTM)

-60.6M

Earnings Y/Y

32.59%

Earnings Q/Q

-60.2%

Price Action

52 Week Range

3.8526.44

(Low)(High)

Last 7 days

0.3%

Last 30 days

1.3%

Last 90 days

-4.6%

Trailing 12 Months

383.3%

VRNA Financial Health

Current Ratio

12.77

VRNA Investor Care

Shares Dilution (1Y)

30.86%

Diluted EPS (TTM)

-0.11

Financials for Verona Pharma

Income Statement (Last 12 Months)
Description	(%) Q/Q	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-96.6%	458,000	13,638,667	26,819,333	40,000,000	26,692,000
Gross Profit	-99.7%	112,000	40,000,000	160,000,000	-	-
Operating Expenses	-29.4%	75,862,000	107,482,000	115,522,000	-	-
S&GA Expenses	-10.2%	26,579,000	29,606,000	32,065,000	-	-
R&D Expenses	-36.7%	49,283,000	77,876,000	83,457,000	-	-
EBITDA	-25.1%	-67,291,000	-53,778,000	-58,153,000	-	-
EBITDA Margin	-10828.2%	-146	-1.34	-1.45	-	-
Earnings Before Taxes	-25.0%	-68,448,000	-54,776,000	-59,132,000	-	-
EBT Margin	-10813.5%	-149	-1.37	-1.48	-	-
Interest Expenses	50.6%	521,000	346,000	340,000	-	-
Net Income	-25.3%	-68,701,000	-54,814,000	-59,116,000	-	-
Net Income Margin	-10846.3%	-150	-1.37	-1.48	-	-
Free Cahsflow	-109.8%	-59,891,000	-28,551,000	-29,227,000	-	-

Balance Sheet					(In Millions)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Assets	24.5%	323	259	275	155	169
Current Assets	26.3%	307	243	258	139	153
Cash Equivalents	27.9%	291	228	232	112	133
Net PPE	-83.6%	0.00	0.00	0.00	0.00	0.00
Goodwill	0%	1.00	1.00	1.00	1.00	1.00
Liabilities	60.0%	46.00	29.00	37.00	44.00	43.00
Current Liabilities	39.4%	27.00	19.00	32.00	39.00	38.00
LT Debt, Non Current	102.8%	20.00	10.00	5.00	5.00	5.00
Shareholder's Equity	20.1%	277	230	237	111	126
Retained Earnings	-5.1%	-350	-333	-322	-306	-288
Additional Paid-In Capital	11.7%	591	529	526	391	388
Shares Outstanding	4.2%	632	606	602	485	483

Cashflow (Last 12 Months)					(In Thousands)
Description	(%) Q/Q	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1
Cashflow From Operations	14.6%	-51,132	-59,862	-69,447	-28,527	-29,215
Share Based Compensation	3.8%	14,663	14,121	13,804	15,926	20,323
Cashflow From Investing	0%	-29.00	-29.00	-30.00	-41.00	-12.00
Cashflow From Financing	49.3%	210,229	140,818	137,303	-4,133	-6,843

Risks for VRNA

What is the probability of a big loss on VRNA?

100%

Probability that Verona Pharma stock will be more than 20% underwater in next one year

100%

Probability that Verona Pharma stock will be more than 30% underwater in next one year.

87.7%

Probability that Verona Pharma stock will be more than 40% underwater in next one year.

*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does VRNA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Verona Pharma was unfortunately bought at previous high price.

Drawdowns

Returns for VRNA

Cumulative Returns on VRNA

5.2%

5-Year Cumulative Returns

64.4%

3-Year Cumulative Returns

What are the long-term rolling returns for VRNA?

FIve years rolling returns for Verona Pharma.

Annualized Returns

Which funds bought or sold VRNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
2023-05-18	NEW YORK STATE COMMON RETIREMENT FUND	new	-	143,000	143,000	-%
2023-05-18	JPMORGAN CHASE & CO	added	11,167	4,319,000	4,369,000	-%
2023-05-16	PERCEPTIVE ADVISORS LLC	reduced	-43.99	-72,638,700	54,894,500	1.62%
2023-05-15	Samsara BioCapital, LLC	unchanged	-	-4,204,760	13,955,600	2.87%
2023-05-15	CITADEL ADVISORS LLC	new	-	5,386,420	5,386,420	-%
2023-05-15	ORBIMED ADVISORS LLC	reduced	-6.81	-33,919,200	85,554,700	1.68%
2023-05-15	Affinity Asset Advisors, LLC	added	44.9	927,073	9,092,650	3.00%
2023-05-15	Artia Global Partners LP	added	126	772,336	1,816,260	0.67%
2023-05-15	Caligan Partners LP	unchanged	-	-1,107,540	3,675,920	2.56%
2023-05-15	Shay Capital LLC	new	-	271,080	271,080	0.05%

Latest Funds Activity

Are funds buying VRNA calls or puts?

Calls

Puts

Are funds bullish or bearish(Calls - Puts)?

Net Call Options

No. of funds that own VRNA

No. of Funds

VRNA Alerts

6 major insider sales recently.

Verona Pharma News

Schedule 13G FIlings of Verona Pharma

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
May 16, 2023	orbimed advisors llc	4.8%	3,777,778	SC 13D/A
Apr 25, 2023	access industries holdings llc	0%	0	SC 13G/A
Apr 20, 2023	perceptive advisors llc	5.6%	4,462,666	SC 13G
Feb 14, 2023	vivo ventures vii, llc	3.8%	23,142,200	SC 13G/A
Feb 14, 2023	ra capital management, l.p.	9.99%	7,691,990	SC 13G/A
Feb 09, 2023	access industries holdings llc	5.45%	32,946,296	SC 13G/A
Feb 06, 2023	wellington management group llp	4.43%	26,770,960	SC 13G/A
Dec 27, 2022	orbimed advisors llc	5.6%	4,260,691	SC 13D/A
Sep 07, 2022	growth equity opportunities fund iv, llc	7.9%	46,447,651	SC 13D/A
Feb 14, 2022	ra capital management, l.p.	9.99%	48,778,172	SC 13G/A

VRNA Fair Value

Show Fair-Value

Recent SEC filings of Verona Pharma

View All Filings

Date Filed	Form Type	Document
May 16, 2023	SC 13D/A	13D - Major Acquisition
May 15, 2023	4	Insider Trading
May 15, 2023	4	Insider Trading
May 11, 2023	144	Notice of Insider Sale Intent
May 11, 2023	4/A	Insider Trading
May 11, 2023	4/A	Insider Trading
May 09, 2023	8-K	Current Report
May 09, 2023	S-8	Employee Benefits Plan
May 09, 2023	10-Q	Quarterly Report
May 03, 2023	144	Notice of Insider Sale Intent

Latest Insider Trading transactions for VRNA

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
2023-05-15	Gupta Rishi	sold	-7,222,480	20.0785	-359,713	-
2023-05-15	ORBIMED ADVISORS LLC	sold	-7,222,480	20.0785	-359,713	-
2023-05-12	ORBIMED ADVISORS LLC	sold	-934,848	21.64	-43,200	-
2023-05-12	Gupta Rishi	sold	-934,848	21.64	-43,200	-
2023-05-11	Gupta Rishi	sold	-1,780,800	22.26	-80,000	-
2023-05-11	ORBIMED ADVISORS LLC	sold	-1,780,800	22.26	-80,000	-
2023-05-03	Rickard Kathleen A.	sold	-76,241	2.6517	-28,752	chief medical officer
2023-05-01	Poll Claire	acquired	-	-	8,328	general counsel
2023-05-01	ZACCARDELLI DAVID	sold	-1,173,420	2.5759	-455,536	president and ceo
2023-05-01	Rickard Kathleen A.	acquired	-	-	15,000	chief medical officer

About Verona Pharma

David S. Zaccardelli

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.

VRNA Income Statement

2023-03-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development	$ 12,610	$ 17,625
Selling, general and administrative	9,589	7,440
Total operating expenses	22,199	25,065
Operating loss	(22,199)	(25,065)
Other income/(expense):
Research and development tax credit	2,313	1,302
Interest income	2,677	15
Interest expense	(293)	(84)
Foreign exchange gain/(loss)	932	(923)
Total other income, net	5,629	310
Loss before income taxes	(16,570)	(24,755)
Income tax expense	(173)	(82)
Net loss	$ (16,743)	$ (24,837)
Profit/(loss) per share, basic (in dollars per share)	$ (0.03)	$ (0.05)
Profit/(loss) per share, diluted (in dollars per share)	$ (0.03)	$ (0.05)
Weighted-average shares outstanding, basic (in shares)	621,451,000	481,942,000
Weighted-average shares outstanding, diluted (in shares)	621,451,000	481,942,000

VRNA Balance Sheet

2023-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 291,415	$ 227,827
Prepaid expenses	1,561	2,499
Tax incentive receivable	11,842	9,282
Other current assets	2,073	3,388
Total current assets	306,891	242,996
Non-current assets:
Furniture and equipment, net	12	73
Goodwill	545	545
Equity interest	15,000	15,000
Right-of-use assets	698	854
Total non-current assets	16,255	16,472
Total assets	323,146	259,468
Current liabilities:
Accounts payable	7,237	2,910
Accrued expenses	17,703	13,752
Current operating lease liabilities	650	675
Taxes payable	424	283
Other current liabilities	509	1,409
Total current liabilities	26,523	19,029
Non-current liabilities:
Term loan	19,809	9,768
Non-current operating lease liabilities	65	205
Total non-current liabilities	19,874	9,973
Total liabilities	46,397	29,002
Commitments and contingencies
Shareholders' equity:
Ordinary £0.05 par value shares; 651,659,630 and 631,338,246 issued, and 631,987,078 and 606,301,054 outstanding, at March 31, 2023 and December 31, 2022, respectively	41,753	40,526
Additional paid-in capital	590,915	529,187
Ordinary shares held in treasury	(1,208)	(1,549)
Accumulated other comprehensive loss	(4,601)	(4,601)
Accumulated deficit	(350,110)	(333,097)
Total shareholders' equity	276,749	230,466
Total liabilities and shareholders' equity	$ 323,146	$ 259,468